NOX4 and Related Biomarkers in ADPKD

Recruiting now

Conditions studied: Autosomal Dominant Polycystic Kidney Disease

In brief

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Key facts

Study ID

NCT04630613

Run by

Mayo Clinic

People needed

60

Starts

2020-07-21

Expected to finish

2027-01-01

Last updated by the study team

2026-01-09

Who can join

Age: 15 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ADPKD (based on Ravine et al. criteria)
• Class 1 A-E according to imaging classification
• Male and female subjects 15 - 40 years of age
• Estimated GFR> 70 mL/min/1.73 m2 (CKD-EPI)
• Ability to provide written, informed consent

You may not qualify if…

• Class 2 according to imaging classification
• Concomitant systemic disease affecting the kidney
• Diabetes mellitus
• Predicted urine protein excretion in >1 g/24 hrs
• Use of antioxidants i.e. vitamins, Nrf2 activators
• Abnormal urinalysis

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.